Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Actinium Pharmaceuticals, Inc. is a biotechnology company focused on developing targeted therapies for cancer treatment, particularly through its lead product candidate, Iomab-B, which is designed for patients with relapsed or refractory acute myeloid leukemia (AML). The company operates primarily in the United States, leveraging its proprietary radioimmunotherapy platform to differentiate itself in the competitive oncology landscape.
Actinium generates revenue primarily through the commercialization of its lead product, Iomab-B, which targets specific cancer cells using radioimmunotherapy. The company possesses a unique competitive advantage through its proprietary technology that enables targeted delivery of radiation to cancer cells, minimizing damage to healthy tissue and potentially improving patient outcomes.
Clinical trial results for Iomab-B, particularly Phase 3 trial outcomes
Regulatory approvals from the FDA for Iomab-B and other pipeline products
Partnership announcements or collaborations with larger pharmaceutical companies
Market adoption rates and sales growth of Iomab-B post-launch
Regulatory changes affecting drug approval processes
Technological disruption from emerging therapies or competitors
Increased competition from other biotech firms developing similar therapies
Potential for larger pharmaceutical companies to dominate the market with more resources
High operating losses leading to potential liquidity issues if funding is not secured
Dependence on external financing to fund ongoing clinical trials and operations
low - The demand for cancer treatments is relatively inelastic, as patients require therapies regardless of economic conditions.
Moderate - Rising interest rates could increase the cost of capital for future financing, impacting R&D investments and operational expansion.
minimal - The company has manageable debt levels and operates with a current ratio of 5.89, indicating strong liquidity.
growth - Investors are likely attracted to the high potential upside from successful drug development.
high - The stock has historically shown high volatility due to the binary nature of clinical trial outcomes.